© 2023 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Marco Meglio
Articles
Eisai Seeks Traditional FDA Approval for Lecenemab with Supplemental BLA Filing
January 11, 2023
Approval of lecanemab under FDA's accelerated pathway requires the company to provide phase 4 study evidence to confirm the agent's clinical effect.